Granules’ generic for ADHD secures U.S. FDA tentative nod
The U.S. FDA approval further strengthens the U.S. generics portfolio of the Granules’, says the company’s CMD. File | Photo Credit: Reuters Granules India, through a subsidiary, has received U.S. Food and Drug Administration’s (FDA’s) tentative approval for its generic of attention deficit hyperactivity disorder drug Adzenys-XR-ODT. The product, indicated for the treatment of ADHD,…
Read More “Granules’ generic for ADHD secures U.S. FDA tentative nod” »